JP2023505543A5 - - Google Patents
Info
- Publication number
- JP2023505543A5 JP2023505543A5 JP2022534860A JP2022534860A JP2023505543A5 JP 2023505543 A5 JP2023505543 A5 JP 2023505543A5 JP 2022534860 A JP2022534860 A JP 2022534860A JP 2022534860 A JP2022534860 A JP 2022534860A JP 2023505543 A5 JP2023505543 A5 JP 2023505543A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- poloxamer
- composition according
- polyethylene glycol
- cabotegravir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945412P | 2019-12-09 | 2019-12-09 | |
| US62/945,412 | 2019-12-09 | ||
| US202062982305P | 2020-02-27 | 2020-02-27 | |
| US62/982,305 | 2020-02-27 | ||
| PCT/IB2020/061582 WO2021116872A1 (en) | 2019-12-09 | 2020-12-07 | Pharmaceutical compositions comprising cabotegravir |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505543A JP2023505543A (ja) | 2023-02-09 |
| JP2023505543A5 true JP2023505543A5 (enExample) | 2023-12-15 |
| JP7703538B2 JP7703538B2 (ja) | 2025-07-07 |
Family
ID=73834567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534860A Active JP7703538B2 (ja) | 2019-12-09 | 2020-12-07 | カボテグラビルを含んでなる医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230045509A1 (enExample) |
| EP (1) | EP4072520B1 (enExample) |
| JP (1) | JP7703538B2 (enExample) |
| KR (1) | KR20220112771A (enExample) |
| CN (1) | CN114786648A (enExample) |
| AU (1) | AU2020402659A1 (enExample) |
| BR (1) | BR112022010574A2 (enExample) |
| CA (1) | CA3164528A1 (enExample) |
| ES (1) | ES3051362T3 (enExample) |
| IL (1) | IL293566A (enExample) |
| MX (1) | MX2022006940A (enExample) |
| TW (1) | TW202135815A (enExample) |
| UY (1) | UY38982A (enExample) |
| WO (1) | WO2021116872A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20220370451A1 (en) * | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| WO2025068743A1 (en) * | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| CA3169348A1 (en) * | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| US20230149408A1 (en) * | 2020-04-15 | 2023-05-18 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2022051198A1 (en) | 2020-09-01 | 2022-03-10 | Viiv Healthcare Company | Combination of cabotegravir and levonorgestrel |
| JP2024500322A (ja) * | 2020-12-07 | 2024-01-09 | ヴィーブ、ヘルスケア、カンパニー | 併用療法 |
| US20240425568A1 (en) * | 2021-12-17 | 2024-12-26 | Viiv Healthcare Company | Combination therapies for hiv infections and uses thereof |
| EP4719608A1 (en) | 2023-05-31 | 2026-04-08 | Gilead Sciences, Inc. | Quinazolinyl-indazole derivatives as therapeutic compounds for hiv |
| CN121909019A (zh) | 2023-09-27 | 2026-04-21 | Viiv保健英国第三有限公司 | 药物组合物 |
| WO2025128498A1 (en) * | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Pharmaceutical compositions |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202602442A (zh) | 2024-03-01 | 2026-01-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 | 給藥方案 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| PT1874117E (pt) | 2005-04-28 | 2013-10-17 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| EP3110422A4 (en) * | 2014-02-24 | 2017-09-06 | Board of Regents of the University of Nebraska | Compositions and methods for the delivery of therapeutics |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| NZ724644A (en) * | 2014-04-11 | 2023-07-28 | Viiv Healthcare Uk No 4 Ltd | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
| EP3197430A1 (en) * | 2014-09-26 | 2017-08-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP3413913B1 (en) * | 2016-02-12 | 2021-11-24 | Cipla Limited | Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer |
| ES3035041T3 (en) * | 2016-06-23 | 2025-08-27 | Viiv Healthcare Co | Compositions and methods for the delivery of therapeutics |
| JP2019524687A (ja) * | 2016-07-01 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 抗体薬物複合体およびこれを用いた治療方法 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| US20210347813A1 (en) * | 2018-04-24 | 2021-11-11 | Viiv Healthcare Uk (No. 5) Limited | Compounds with hiv maturation inhibitory activity |
| US11944611B2 (en) * | 2018-07-16 | 2024-04-02 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
| US11541055B2 (en) | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN113382737B (zh) * | 2018-11-29 | 2025-06-03 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| EP3934760A1 (en) * | 2019-03-06 | 2022-01-12 | GlaxoSmithKline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| EP3962603A1 (en) * | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| KR102932817B1 (ko) * | 2019-06-19 | 2026-03-04 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체 |
| JP7719769B2 (ja) * | 2019-09-11 | 2025-08-06 | ザ スクリプス リサーチ インスティテュート | 抗ウイルスプロドラッグ及びその医薬組成物 |
-
2020
- 2020-12-07 CA CA3164528A patent/CA3164528A1/en active Pending
- 2020-12-07 ES ES20824345T patent/ES3051362T3/es active Active
- 2020-12-07 AU AU2020402659A patent/AU2020402659A1/en not_active Abandoned
- 2020-12-07 TW TW109143111A patent/TW202135815A/zh unknown
- 2020-12-07 EP EP20824345.1A patent/EP4072520B1/en active Active
- 2020-12-07 UY UY0001038982A patent/UY38982A/es not_active Application Discontinuation
- 2020-12-07 IL IL293566A patent/IL293566A/en unknown
- 2020-12-07 WO PCT/IB2020/061582 patent/WO2021116872A1/en not_active Ceased
- 2020-12-07 US US17/756,971 patent/US20230045509A1/en active Pending
- 2020-12-07 CN CN202080085115.9A patent/CN114786648A/zh active Pending
- 2020-12-07 BR BR112022010574A patent/BR112022010574A2/pt not_active Application Discontinuation
- 2020-12-07 KR KR1020227018750A patent/KR20220112771A/ko not_active Withdrawn
- 2020-12-07 JP JP2022534860A patent/JP7703538B2/ja active Active
- 2020-12-07 MX MX2022006940A patent/MX2022006940A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heuschkel et al. | Microemulsions—modern colloidal carrier for dermal and transdermal drug delivery | |
| Spreen et al. | Long-acting injectable antiretrovirals for HIV treatment and prevention | |
| HRP20250278T1 (hr) | Puferovane formulacije eksendina (9-39) | |
| JP2022191257A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| JP2019503365A5 (enExample) | ||
| EP2292235A3 (de) | Methotrexat-Lösungen | |
| JP2022505928A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2018048179A5 (enExample) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| RU2021137159A (ru) | Стабильные водные составы на основе антител | |
| JP2005343897A5 (enExample) | ||
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2015525763A5 (enExample) | ||
| JP2019524893A (ja) | エダラボン・（＋）−２−ボルネオールの舌下投与用医薬組成物 | |
| CN108884053A (zh) | 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法 | |
| JP2017528497A5 (enExample) | ||
| JP2015537009A5 (enExample) | ||
| TW202523329A (zh) | 阿立哌唑注射用製劑之投予方法 | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| RU2014113941A (ru) | Суспензия для перорального введения | |
| JP2016537364A5 (enExample) |